Copper Complex Halts Botulinum Neurotoxin Poisoning
|
By HospiMedica International staff writers Posted on 12 Jun 2017 |
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Latest Critical Care News
- Inhaled Therapy Uses Modified Bacteria to Break Down Pseudomonas Biofilms
- Miniature Wearable Sensor Enables Continuous Cuffless Blood Pressure Monitoring
- Studies Support AI-ECG for Detecting Suspected Hypertrophic Cardiomyopathy
- Updated Staging System Standardizes Cardiogenic Shock Assessment
- Moldable Sensor Could Support Neck Muscle Monitoring and Rehabilitation
- Routine Opt-Out Screening Helps Increase Detection of Adolescent STIs
- Personalized fMRI-Guided TMS May Improve Severe OCD Symptoms
- Ultrasound Implant Could Help Monitor Spinal Cord Recovery After Surgery
- Paper-Based Patch Integrates Sweat Sensors and Drug-Delivery Microneedles
- Circuit-Free Smart Patch Uses Smartphone Camera to Monitor Pulse and Vessel Stiffness

- Chest Digital Twin Guides Light Therapy Dosing for Pneumonia
- Intraoperative Drug Combination Reduces Kidney Injury in Septic Shock Surgery
- Wirelessly Powered Implant Targets Excess Glucose in the Blood
- Noninvasive Brain-Computer Interface Enables Responses in Some Unresponsive ICU Patients
- U.S. Launch Expands Kidney Replacement Therapy Options With Integrated Anticoagulation
- Smart Medical Adhesive Patch Uses Heat to Enable Gentle Removal
Channels
Artificial Intelligence
view channel
AI Analysis of Smartwatch ECGs May Help Detect Weakened Heart Function
Left ventricular systolic dysfunction (LVSD) occurs when the heart’s main pumping chamber does not contract effectively. The condition can remain asymptomatic for some time but may progress to symptomatic... Read more
AI Tool Speeds Echocardiogram Reporting With Comparable Accuracy
Echocardiography is the most widely used form of cardiac imaging, playing a key role in diagnosing heart disease and guiding treatment decisions. However, reviewing ultrasound images and documenting cardiac... Read moreSurgical Techniques
view channel
Fluorescence Imaging Reveals Nerves Under Normal Operating-Room Lighting
Preventing unintended nerve injury remains a major concern during surgery, particularly in complex anatomical regions where nerves can be difficult to distinguish from surrounding tissue.... Read more
Programmable Microwave Ablation System Gains CE Mark for Minimally Invasive Tissue Ablation
Hospitals continue to seek minimally invasive approaches that simplify procedural planning and provide controlled energy delivery for tissue ablation. Thermal ablation systems are used across multiple... Read more
Minimally Invasive Balloon Procedure May Redirect Blood Flow During Cardiac Arrest
Out-of-hospital cardiac arrest has a low survival rate, and patients who do not respond to prolonged advanced resuscitation have few remaining treatment options. During cardiopulmonary resuscitation, blood... Read morePatient Care
view channelVirtual Reality Program May Reduce Anxiety Before Pediatric Surgery
Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more
Video-Based Support Helps Older Adults Clarify Kidney Disease Treatment Preferences
Advanced chronic kidney disease (CKD) involves progressive loss of kidney function that can lead to kidney failure and difficult treatment decisions. For older adults, these decisions may include choosing... Read moreMedical Imaging
view channel
Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis
Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more
MRI Test Identifies Candidates for Lower-Dose Radiotherapy in HPV Throat Cancer
Human papillomavirus (HPV)-positive oropharyngeal cancer is a throat cancer linked to HPV infection. Its incidence is rising, and many patients receive high-dose radiotherapy that can cause long-term swallowing... Read moreHealth IT
view channel
Clinical Decision Support Tool Automates CKD Risk Assessment in Primary Care
Chronic kidney disease (CKD) requires timely diagnosis, risk assessment, and coordinated treatment in primary care. Delayed recognition can affect decisions about testing, blood pressure control, cardiovascular... Read more
EHR Alerts Support Dosing, Sedation, and Shock Recognition in Cardiac Care
Electronic health record alerts can add to clinician workload when they are poorly targeted. In critical cardiac care, however, delayed decisions can affect treatment timing, sedation exposure, and escalation... Read morePoint of Care
view channel
New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read moreBusiness
view channel
Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings
Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more







